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1. Introduction 
Although a great deal is known about protein syn- 
thesis, the means by which ribosomes carry out their 
nmltiple functions and the mechanisms for their con- 
trol are not defined. The role of modified nucleotides, 
for example, is essentially unknown. About 3--4% of 
the nucleotides in eukaryotic ribosomal RNA are 
modified; 1-2% of the ribose residues are 2'-0- 
methylated and 10% of the uridylic acid residues are 
converted to pseudouridylic acid [1,2]. Some of 
these modifications are present in the entire RNA 
population while others are restricted to a fraction of 
the molecules [3,4]. Methylation appears to be essen- 
tial in ribosome maturation [5] and ribose-methyl- 
ation is largely or completely restricted to the mature 
RNA species [6]. It has been suggested that methyl- 
ation may render crucial sequences resistant to 
cyclizing ribonucleases [7]. Alternately, the presence 
of partially methylated or modified sequences has 
suggested that they may exert some modulating or 
control activity. 
Recent studies on the primary sequence of 
Novikoff ascites hepatoma 5.8S rRNA have revealed 
two sequences containing 2'-O-methylribose, A -A -  
U -U-Gm-C-A-Gp and G-G-Um-G-G-A-Up 
and two sequences containing pseudouridylic acid, 
C-ff-Gp and ff-Gp [8,9]. The 2'-O-methyl guanylic 
acid residue was present in molar amounts while Um 
was only found in about 20% of the molecules. Simi- 
larly, the ff-Gp sequence was present in every mole- 
cule while C-ff-Gp was only found in half molar 
amounts. An experimental pproach to the role of 
modified nucleotides in ribosomal RNA requires an 
ability to alter the levels of modification for correla- 
tion with its biological function. As a prelimin~lry 
approach towards understanding the role of these 
modified nucleotides, we have examined 5.8S rRNAs 
from various tissues of different growth rate and 
development in search of physiologically related 
changes. 
2. Materials and methods 
The tissues used in these studies were human, rat, 
mouse or chick in origin. Normal BALB/C mice and 
the transplanted DMBA(dimethylbenzanthracene)- 
induced mouse mammary tumors were kindly provided 
by Dr D. Medina. Mouse myeloma MPC-1 1 cell RNA, 
HeLa cells and secondary chick embryo cells were pro- 
vided by Drs E. Murphy, P. N. Rao and J. Norris, respec- 
tively. Male Sprague Dawley rats were used for nor- 
mal rat tissues and to maintain Novikoff hepatoma 
ascites cells. Cells were labeled with 5-50 mC: of 
[32P]orthophosphate in vitro or in vivo as previously 
described [ 10] ; for regenerating liver the isotope was 
injected interperitoneally 48h after the partial 
hepatectomy and the animal was sacrificed 24 h later. 
Whole cell RNA was extracted with a phenol-SDS 
buffer at 65°C and the 5.8S rRNA waKfractionated 
on polyacrylamide g l slabs [8,9]. The purified RNA 
was digested with pancreatic or TI ribonucleases and 
the resulting oligonucleotides were fractionated by 
two-dimensional electrophoresis [ 11 ]. The modified 
fragments were identified as previously reported [8]. 
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3. Results and discussion 
The autoradiographs in fig.1 compare the pan- 
creatic or TI ribonuclease digestion 'fingerprints' of 
Novikoff hepatoma nd normal rat liver 5.8S rRNAs. 
Both 'fingerprints' are identical except for quantita- 
tive differences in the methylation of G-G-U-G-  
G-A-Up to G-G-Um-G-G-A-Up.  The Novikoff 
hepatoma contains little G-G-Um-G-G-A-Up 
and large amounts of the unmethylated quivalents 
G-G-Up and G-G-A-Up (fig.lA). In contrast, he 
normal rat liver contains alarge amount of G-G-Um-  
G-G-A-Up and only traces of G-G-Up and G-G-  
A-Up. Table 1 shows that the hepatoma and normal 
liver RNAs both contained approx. 1 m91 of Gm-Cp 
but only 0.2 and 0.7 mol of G-G-Um-G-G-A-Up,  
respectively. Table 2 shows that the pseudouridylic 
acid content was relatively constant. Each RNA which 
was analyzed contained approx. 1 mol of ~k-Gp and a 
half tool of C-~k-Gp. 
Table 1 summarizes the levels of methylation i
twelve different tissues of human, rat, mouse or chick 
origin. In all cases the level of methylation for the 
Gm-Cp fragments was high; virtually every molecule 
of 5.8S rRNA appeared to contain this sequence. In
contrast, he 2'-O-methyl uridine content varied 
widely; the highest was 0.72 mol in normal rat liver 
5.8S rRNA and the lowest was 0.17 mol in HeLa 
cells. These differences were tissue specific rather than 
species pecific; in the mouse, for example, kidney, 
liver and spleen had relatively high methylation levels, 
all greater than 0.6 mol. Pregnant mouse mammary 
gland and embryo RNA had intermediate levels of 
methylation and both of the malignant tissues con- 
tained little 2'-O-methyl uridine, 0.2 and 0.3 mol for 
the myeloma nd mammary tumor, respectively. 
These results indicate that while most nucleotide 
modifications in 5.8S rRNA are relatively constant in 
a large number of tissues, the level of 2'.0- methyla- 
tion in the G-G- -Um-G-G-A-Up sequence varies 
Fig.lA 
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Fig.1. Autoradiographs for two-dimensional Iractionations of pancreatic (A) and T~ (B) RNase digests of 32P-labeled normal rat 
liver or Novikoff hepatoma 5.8S rRNA. Electrophoresis was from fight to left on cellulose-acetate  pH 3.5, and from top to 
bottom on DEAE paper in 7% formic acid. The spots containing modified nucleotides are labeled to correspond to the text. 
significantly. The role of this 2'-O- methyl uridylic 
acid residue and the significance of these differences, 
however, are unclear. Ribosomal RNA precursors in 
cells with low methylation such as the Novikoff 
hepatoma ppear to be processed normally and do 
not require 2'-O-methyl uridylic acid for maturation. 
Tissues with high levels of methylation such as nor- 
mal rat liver carry out protein synthesis efficiently 
and do not appear to be inhibited by methylation. 
Any effects, therefore, must be more subtle and not 
detectable by such gross measurements. Um may 
stabilize the secondary structure of 5.8S rRNA as has 
been suggested for tRNA [12] and this may alter its 
activity within the ribosome. Alternately, the 2'-0- 
methyl uridylic acid containing sequence may form a 
binding site for some class of messenger or tRNA or 
specific protein with the methylated nucleotide 
controlling this interaction. 
Aberrant nucleic acid methylation has previously 
been reported in tumor tissues and has been suggested 
as a factor in malignant transformation [13]. The 
apparently excessive tRNA methyltransferase activi- 
ties in tumors [14] have led to the assumption that 
overmethylation may occur in oncogenesis. In  
contrast, the present studies uggest some site specific 
undermethylation in the ribosomal RNAs of malig- 
nant cells. In each series of related tissues, the lowest 
levels of methylation were found in the tumor. How- 
ever, there was some correlation with growth rate and 
it is not clear whether this change is required in malig- 
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Table 1 
2'-O-Methylated nucleotides in5.8S ribosomal RNA from different issues 
GGUmGGAUp GmCp 
Source of 5.8S rRNA (moles) (moles) 
Normal rat liver 0.72 1.03 
Normal mouse liver 0.69 - 
Normal mouse spleen 0.62 - 
Normal mouse kidney 0.61 1.16 
Pregnant mouse mammary gland 0.51 0.98 
Secondary chick embryo 0.49 1.04 
Mouse embryo 0.40 0.99 
Transplanted DMBA induced 
mouse mammary tumor 0.34 - 
Regenerating rat liver 0.31 0.90 
Novikoff Ascites hepatoma cells 0.23 0.90 
Mouse myeloma MPC-11 0.18 1.02 
HeLa cells 0.17 0.96 
32 P-labeled 5.8S rRNA was digested with T a RNase and the oligonucleotide 
fragments were separated as described in fig.1. Fragments containing 2'-O-methyl- 
ated nucleotides were identified as previously described [8,9]. The molar yields 
were calculated in assuming 1 GGUGGAU and 8 GC oligonucleotide fragments 
per molecule [9]. Mouse embryo and mammary gland RNA were prepared from 
12-15 day pregnant mice. 
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nant transformation. Undermethylation has also been 
described in specific sequences of ribosomal high mol. 
wt RNAs [4,7,15] but no tissue comparison was 
made. Therefore, it is also unclear whether the dif- 
ferences in methylation reported here are unique or 
represent a coordinated series of changes in ribosomal 
RNA in general. Nevertheless, the observation remains 
Table 2 
Pseudouridylic a id residues in 5.8S ribosomal RNA from 
different issues 
C-~0-Gp ~-Gp 
Source of 5.8S rRNA (moles) (moles) 
HeLa cells 0.59 0.98 
Mouse myeloma MPC-11 0.64 0.82 
Novikoff Ascites hepatoma cells 0.54 1.01 
Secondary chick embryo 0.39 1.20 
Normal mouse fiver 0.62 0.94 
sa P-labeled 5.8S rRNA was digested with T 1 RNase and 
the oligonucleotide fragments were separated as described in 
rigA. Fragments containing pseudouridyfic a id were analyzed 
as previously described [8,9]. The molar yields were calcu- 
lated assuming 1 CUG and 3 UG ofigonucleotide fragments 
per molecule [9]. 
an attractive xperimental system for examining the 
enzymology, function and control of rRNA methyla- 
tion and possible relationships to cancer. 
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